DiaMedica Therapeutics Inc. has announced the successful closing of a $30.1 million private placement of common shares to accredited investors. The clinical-stage biopharmaceutical company, which is focused on developing novel treatments for conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke, sold approximately 8.6 million common shares at a price of $3.50 per share. After deducting estimated offering expenses, DiaMedica received net proceeds of approximately $29.9 million. With these proceeds, the company's cash, cash equivalents, and short-term investments would have been $67.2 million as of March 31, 2025, on a pro forma basis. DiaMedica has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale of the common shares issued in this private placement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.